Archived Monthly Oncology Tumor Boards: Management of Early-Stage Non-Small Cell Lung Cancer
Health care providers need to know about the recent updates to the NCCN Guidelines for Non-Small Cell Lung Cancer to provide the best care for their patients with NSCLC, including adverse reactions that may occur with use of the new neoadjuvant and adjuvant systemic therapy regimens.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Archived Monthly Oncology Tumor Boards: Sequencing Therapies for Patients with Metastatic HER2-Negative Breast Cancer
With expanding treatment options, clinicians should understand important criteria used in selecting optimal first- and subsequent-line therapies for individuals with metastatic breast cancer. It is important for clinicians to stay up-to-date with the available treatment options to integrate new evidence-based data into their clinical practice, and being familiar with the toxicity profiles is important to optimize patient outcomes.
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
NCCN Guidelines® Insights - Mesothelioma: Pleural, Version 1.2024
These NCCN Guidelines Insights highlight significant updates to the NCCN Guidelines for Mesothelioma: Pleural, including revised guidance on disease classification and systemic therapy options.
Category
  • Mesothelioma
Format
  • Monograph/Journal Supplement
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Advances in the Management of Metastatic Breast Cancer with SABCS Updates
This activity covers the following presentations:Advances in the Management of HR-Positive Metastatic Breast Cancer with SABCS UpdatesAdvances in the Management of HER2-Positive Metastatic Breast Cancer with SABCS Updates
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 ASWB continuing education credit
  • 1.00 Participation
Locoregional Management of Breast Cancer with SABCS Updates
This activity covers the following presentations:Updates to Radiation Therapy for DCIS and Invasive Breast Cancer with SABCS UpdatesSurgical Management of Invasive Breast Cancer with SABCS Updates
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 ASWB continuing education credit
  • 1.25 Participation
Multigene and Biomarker Testing in Breast Cancer
This activity covers the following presentations:Biomarkers and Gene Panel Testing in Early-Stage Breast CancerNext-Generation Sequencing Testing in the Metastatic Setting
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 ASWB continuing education credit
  • 1.00 Participation
Neoadjuvant/Adjuvant Treatment for Breast Cancer with SABCS Updates
This activity covers the following presentations:
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • 1.25 AAPA Category 1 CME credit
  • 1.25 ACPE contact hours
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 ANCC contact hours
  • 1.25 ASWB continuing education credit
  • 1.25 Participation
Recorded Presentation from the NCCN Pharmacy Updates: The Growing Impact of Pharmacogenomics Across the Oncology Landscape
Advances in pharmacogenomics are widespread in the treatment of cancer. The ongoing research in pharmacogenomics has played a vital role in the diagnosis and treatment of oncologic disease states. It is imperative for the interprofessional oncology care team to have a strong understanding of pharmacogenomics and the ability to correctly apply the standard of care for their patients.
Category
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Issues with Sexuality and Sexual Function in Patients with Breast Cancer
Addressing sexual health is an essential step during the treatment of breast cancer. Healthcare providers should discuss with patients the potential changes in sexual function and sexuality related to cancer treatment as well as the measures that are available to overcome these challenges.
Category
  • Breast Cancer
  • Survivorship
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 ASWB continuing education credit
  • 1.00 Participation
Cardiovascular Health After Breast Cancer Treatment
Breast cancer survivors are at increased risk of cardiovascular disease (CVD) and death from cardiovascular complications. Therefore, CVD risk assessment and counseling on CVD risk factor management are recommended for all cancer survivors throughout the survivorship continuum.
Category
  • Breast Cancer
  • Survivorship
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation

Pages